APA (7th ed.) Citation

Vermeulen, S., Awada, G., Keyaerts, M., Neyns, B., & Everaert, H. (2021). Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Current Oncology, 28(3), 1630. https://doi.org/10.3390/curroncol28030152

Chicago Style (17th ed.) Citation

Vermeulen, Sim, Gil Awada, Marleen Keyaerts, Bart Neyns, and Hendrik Everaert. "Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome." Current Oncology 28, no. 3 (2021): 1630. https://doi.org/10.3390/curroncol28030152.

MLA (9th ed.) Citation

Vermeulen, Sim, et al. "Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome." Current Oncology, vol. 28, no. 3, 2021, p. 1630, https://doi.org/10.3390/curroncol28030152.